Publications by authors named "T Babacan"
Article Synopsis
- This study aims to explore how inflammatory markers impact prognosis in patients with metastatic breast cancer.
- During the study, 81 patients were monitored, revealing that high levels of C-reactive protein, ferritin, and beta-2 microglobulin were linked to significantly shorter overall survival compared to those with normal levels.
- The findings suggest that serum CRP, ferritin, and β2-M could serve as important indicators for predicting overall survival in metastatic breast cancer patients.
Article Synopsis
- The study aimed to identify demographic and histopathological differences in breast cancer patients across various age groups, highlighting the need for larger research to clarify existing controversies.
- A total of 3,325 women diagnosed with breast cancer were examined, revealing that older postmenopausal women tended to have distinct reproductive histories compared to younger premenopausal women who had worse tumor characteristics.
- The findings suggest a future necessity for targeted screening programs for younger women, alongside increased education and self-examination practices to enhance early detection of breast cancer.
Purpose: Development of metastasis in patients with breast cancer (BC) is the most important negative prognostic factor and this process mainly begins with lymphatic involvement. Therefore, axillary, subclavicular, internal mammary or supraclavicular nodal involvement is a crucial step before metastasis. Anatomical differences between the right and left lymphatic drainages of the breasts may significantly affect the rate, site and time to development of distant metastasis.
View Article and Find Full Text PDFPurpose: Educational status may be an important parameter in assessing breast cancer risk and prognosis. The purpose of this study was to investigate the correlation between the level of education and clinicopathological characteristics of breast cancer, including tumor grade, HER-2 and estrogen receptor (ER) status, tumor size, axillary lymph node involvement and metastasis.
Methods: The study included 1800 women who were diagnosed with invasive breast cancer during 2005-2013 at Hacettepe University Cancer Institute.
Purpose: Optimal duration of adjuvant trastuzumab therapy in early-stage HER2-positive, lymph node-negative breast cancer is unknown. To establish this, we compared 1-year and 9-week trastuzumab regimens in HER2-positive, lymph node-negative early-stage breast cancer patients.
Methods: We retrospectively analyzed 4374 breast cancer patients.